000 03682nam a22005895i 4500
001 978-3-031-50415-0
003 DE-He213
005 20251030112933.0
007 cr nn 008mamaa
008 240903s2024 sz | s |||| 0|eng d
020 _a9783031504150
_9978-3-031-50415-0
024 7 _a10.1007/978-3-031-50415-0
_2doi
050 4 _aRM300-666
072 7 _aMMG
_2bicssc
072 7 _aMED071000
_2bisacsh
072 7 _aMKG
_2thema
100 1 _aMittal, Bhavishya.
_eauthor.
_4aut
_4http://id.loc.gov/vocabulary/relators/aut
_983587
245 1 0 _aSustainable Global Health Systems and Pharmaceutical Development
_h[electronic resource] /
_cby Bhavishya Mittal.
250 _a1st ed. 2024.
264 1 _aCham :
_bSpringer International Publishing :
_bImprint: Springer,
_c2024.
300 _aXXIX, 247 p. 109 illus., 92 illus. in color.
_bonline resource.
336 _atext
_btxt
_2rdacontent
337 _acomputer
_bc
_2rdamedia
338 _aonline resource
_bcr
_2rdacarrier
347 _atext file
_bPDF
_2rda
490 1 _aAAPS Advances in the Pharmaceutical Sciences Series,
_x2210-738X ;
_v60
505 0 _aHealth Care Industry -- Reimbursement and Pricing -- Current Stage of Pharmaceutical Development -- Desired Future State of Pharmaceutical Development -- Case Studies I -- Case Studies II -- Case Studies III.
520 _aDespite being an economically intense activity, the current state of drug product development makes a limited effort to integrate economics into product design and development. For example, pharmaceutical scientists are excellent at a data-driven decision-making process that requires technical elements and a few strategic elements. However, there is minimal integration of financial valuation elements (commonly employed in other high tech industries such as fine chemicals, automotive, aerospace, etc.) into pharmaceutical drug development. Unfortunately, this hurts the sustainability of the health system of which these products will be a part in the future. A desirable future state is the one that integrates fundamentals of economics in product design and development so that the decision-making is parameterized, the cost of goods could be lowered, wastage can be reduced, patient-centricity is built into the design, and manufacturing/distribution efficiencies can be gained. The financial benefits of such an approach could allow for these savings to be passed on to the stakeholders and improve the value proposition of pharmaceuticals, which is critical to maintaining the innovation potential. This book hopes to introduce the reader to this desired future state of pharmaceutical drug development. .
650 0 _aPharmacology.
_967844
650 0 _aPharmacy.
_964666
650 0 _aPublic health.
_961312
650 0 _aPharmaceutical chemistry.
_967843
650 0 _aEpidemiology.
_965983
650 1 4 _aPharmacology.
_967844
650 2 4 _aPharmacy.
_964666
650 2 4 _aPublic Health.
_961312
650 2 4 _aPharmaceutics.
_967846
650 2 4 _aEpidemiology.
_965983
710 2 _aSpringerLink (Online service)
773 0 _tSpringer Nature eBook
776 0 8 _iPrinted edition:
_z9783031504143
776 0 8 _iPrinted edition:
_z9783031504167
776 0 8 _iPrinted edition:
_z9783031504174
830 0 _aAAPS Advances in the Pharmaceutical Sciences Series,
_x2210-738X ;
_v60
_967850
856 4 0 _uhttps://doi.org/10.1007/978-3-031-50415-0
912 _aZDB-2-SBL
912 _aZDB-2-SXB
999 _c63047
_d63047